fig5
From: A responder-informed gut microbial consortium enhances anti-PD-1 efficacy in a mouse cancer model
Figure 5. UJ-04 enhances the efficacy of anti-PD-1 in a mouse melanoma model. (A) Experimental schema for antibiotic treatment, tumor implantation, UJ-04 administration, and anti-PD-1 therapy. (B) Tumor growth curves for each treatment group. Data are shown as mean ± SEM (n = 4-5 mice per group). (C) Representative images of tumors resected at the experimental endpoint. (D) Endpoint tumor weight. (E) Individual tumor growth trajectories (“spaghetti” plots). Statistical analyses were performed as described in Methods. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. ABX: Antibiotics; AMP: ampicillin; STR: streptomycin; CST: colistin; UJ-04: four-strain consortium; PBS: phosphate-buffered saline; SEM: standard error of the mean.
